CAS: 514-47-6; 4,4,10,13,14-Pentamethyl-17-(6-Methylhept-5-En-2-yl)-2,3,4,5,6,7,10,11,12,13,14,15,16,17-Tetradecahydro-1H-Cyclopenta[a]Phenanthren-3-Ol

该化合物是属于euphane 三角类的血清化合物,其特点是四环结构,具有特定的氢氧化模式,有助于其生化活动,该化合物与生物途径,特别是与植物防护机制和二级代谢物合成可能发生相互作用,因此对植物化学研究感兴趣.Euphadienol在标准实验室条件下表现出中等稳定性,适合分析和实验应用.其结构特征允许衍生,有利于对结构-活动关系进行进一步研究.该化合物通常与自然来源隔离,需要染色净化才能达到高纯度(>95%);研究人员对Euphadienol在三乙型生物合成和相关酶过程中的作用具有价值.

结构式图片

上下游产品

3β-Hydroxy-25,26,27-Trisnor(5α,13α,14β,17α)Lanost-8-En-24-Al 124816-98-4
Eupha-8,24-Diene-3β-Ol-7-One

合成工艺路线路线简述

    📜Eupha-8,24-Diene-3β-Ol-7-One置于甲醇,Sodium Tetrahydroborate体系中,化学反应生成 大戟二烯醇
    参考文献: Process For The Preparation Of Lanosta-8-Ene Compou[fr] Procédé De Préparation De Composés Lanosta-8-ènes
    标题: Process For The Preparation Of Lanosta-8-Ene Compou[fr] Procédé De Préparation De Composés Lanosta-8-ènes
    摘要:本发明涉及一种以lanosta-8-Ene-7-One或lanosta-8-Ene-7-Ol化合物为起始原料制备lanosta-8-Ene化合物的方法.

    海关参考信息

    专利信息


    专利号:WO-2020121335-A1
    优先权日:2018-12-14
    标题:A process for producing tirucalladienol for synthesis of limonoids
    发明人:HIREKODATHAKALLU VENKATARAMAIAH THULASIRAM; PANDREKA AVINASH; PATIL CHAYA SHIVANAGOUDA
    权利人:COUNCIL SCIENT IND RES
    摘要:The invention relates to the construction of recombinant DNA constructs encoding tirucalladienol synthase; and squalene epoxidase operably linked to a regulatory sequence. The production of tricualldienol in a yeast is increased by coexpression with squalene epoxidase. Further, tirucalladeinol synthase engineering leads to increase in the efficiency of the synthesis process towards tirucalladienol.

    专利号:US-2019029993-A1
    优先权日:2017-07-26
    标 题 :Quality of life extension therapies relating to aging, food allergies, pain and reduced vigor by managing molecular, cellular and subcellular biochemical requirements of mitochondria and other organelle processes
    发明人:POSTREL RICHARD
    权利人:POSTREL RICHARD
    摘要:This invention provides compositions, systems and methods that improve and/or optimize the health and performance of animals, especially mammals including humans, canines, equines, felines, etc. Key aspects of the principle invention and its parts include the monitoring, management and modulation of the body's natural cannabinoid systems through its native mechanisms thereby optimizing its processes by supplementation with endogenously occurring components and/or by administering synthetic compounds. The invention selects from multiple available resources to modify and/or rebalance an individual system or it may be applied across interconnected systems. The encompassing system that is intricately involved in the operations and intensities, e.g., the balancing of most other systems of our bodies, relates to cannabinoid compounds and their receptors. The cannabinoid pathways can be coordinated in rebalancing multiple and various metabolic pathways. Compositions comprising compounds that slow degradation of native endocannabinoids, that stimulate their production and/or compounds that act on cannabinoid receptors within the body are featured in systems and methods of this invention. The activated and rebalanced cannabinoid systems then become adept at modulating and the rebalancing of the numerous systems in which they participate to improve one or more systems including, but not limited to: normal and/or abnormal stresses of life, environmental influences, genomic or epigenomic irregularities and/or normal or accentuated processes of aging. Specifically targeted systems may include, but are not limited to, those involved in: cellular and/or mitochondrial metabolism, corticosteroid synthesis and effects, appetite, allergy and immunity, sleep and waking, etc. Practicing the invention selects from multiple approaches that may be used independently or in concert to compensate for a variety of concerns. Supplementing dietary intake to rebalance metabolism and/or its metabolic responses—including immunogenic or allergic responses to pathogenic and/or environmental stresses is one focus. Additional features of the invention may include: compensating for failing or decreasing androgen hormone levels as an animal continues to age, rebalancing the organism's metabolism through providing mitochondrial supplements, and serially revisiting effects of the early stages of treatment to redirect or improve activity of all aspects of life and metabolism.

    专利号:US-2019030044-A1
    优先权日:2017-07-26
    标 题:Human life extension therapy through molecular, cellular and subcellular management of biochemical requirements of mitochondria and of other organelle processes associated with the advent of disease and/or aging
    发明人:POSTREL RICHARD
    权利人:POSTREL RICHARD
    摘要:This invention provides compositions, systems and methods that improve and/or optimize the health and performance of animals, especially mammals including humans, canines, equines, felines, etc. Key aspects of the principle invention and its parts include the monitoring, management and modulation of the body's natural cannabinoid systems through its native mechanisms thereby optimizing its processes by supplementation with endogenously occurring components and/or by administering synthetic compounds. The invention selects from multiple available resources to modify and/or rebalance an individual system or it may be applied across interconnected systems. The encompassing system that is intricately involved in the operations and intensities, e.g., the balancing of most other systems of our bodies, relates to cannabinoid compounds and their receptors. The cannabinoid pathways can be coordinated in rebalancing multiple and various metabolic pathways. Compositions comprising compounds that slow degradation of native endocannabinoids, that stimulate their production and/or compounds that act on cannabinoid receptors within the body are featured in systems and methods of this invention. The activated and rebalanced cannabinoid systems then become adept at modulating and the rebalancing of the numerous systems in which they participate to improve one or more systems including, but not limited to: normal and/or abnormal stresses of life, environmental influences, genomic or epigenomic irregularities and/or normal or accentuated processes of aging. Specifically targeted systems may include, but are not limited to, those involved in: cellular and/or mitochondrial metabolism, corticosteroid synthesis and effects, appetite, allergy and immunity, sleep and waking, etc. Practicing the invention selects from multiple approaches that may be used independently or in concert to compensate for a variety of concerns. Supplementing dietary intake to rebalance metabolism and/or its metabolic responses—including immunogenic or allergic responses to pathogenic and/or environmental stresses is one focus. Additional features of the invention may include: compensating for failing or decreasing androgen hormone levels as a human continues to age, rebalancing the organism's metabolism through providing mitochondrial supplements, and serially revisiting effects of the early stages of treatment to redirect or improve activity of all aspects of life and metabolism.

    专利号:CN-108477167-A
    优先权日:2018-03-26
    标题:A method for promoting the synthesis of terpenoids in Kansui

    专利号:US-2020078333-A1
    优先权日:2016-12-21
    标 题 :Healthier Aging in Domesticated Animals
    发明人:POSTREL RICHARD
    权利人:POSTREL RICHARD
    摘要:This invention provides compositions, systems and methods that improve and/or optimize the health and performance of animals, especially mammals including humans, canines, equines, felines, etc. Key aspects of the principle invention and its parts include the monitoring, management and modulation of the body's natural cannabinoid systems through its native mechanisms thereby optimizing its processes by supplementation with endogenously occurring components and/or by administering synthetic compounds. The invention selects from multiple available resources to modify and/or rebalance an individual system or it may be applied across interconnected systems. The encompassing system that is intricately involved in the operations and intensities, e.g., the balancing of most other systems of our bodies, relates to cannabinoid compounds and their receptors. The cannabinoid pathways can be coordinated in rebalancing multiple and various metabolic pathways. Compositions comprising compounds that slow degradation of native endocannabinoids, that stimulate their production and/or compounds that act on cannabinoid receptors within the body are featured in systems and methods of this invention. The activated and rebalanced cannabinoid systems then become adept at modulating and the rebalancing of the numerous systems in which they participate to improve one or more systems including, but not limited to: normal and/or abnormal stresses of life, environmental influences, genomic or epigenomic irregularities and/or normal or accentuated processes of aging. Specifically targeted systems may include, but are not limited to, those involved in: cellular and/or mitochondrial metabolism, corticosteroid synthesis and effects, appetite, allergy and immunity, sleep and waking, etc. Practicing the invention selects from multiple approaches that may be used independently or in concert to compensate for a variety of concerns. Supplementing dietary intake to rebalance metabolism and/or its metabolic responses—including immunogenic or allergic responses to pathogenic and/or environmental stresses is one focus. Additional features of the invention may include: compensating for failing or decreasing androgen hormone levels as an animal continues to age, rebalancing the organism's m

    专利号:CN-105246866-B
    优先权日:2013-05-31
    标题:The method of synthesis ingenol and its intermediate

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Dutra RC, Bicca MA, Segat GC, Silva KA, Motta EM, Pianowski LF, Costa R, Calixto JB. The antinociceptive effects of the tetracyclic triterpene euphol in inflammatory and neuropathic pain models: The potential role of PKCε. Neuroscience. 2015 Sep 10;303:126-37. doi: 10.1016/j.neuroscience.2015.06.051. Epub 2015 Jul 2. doi: 10.1371/journal.pone.0140249. eCollection 2015.
    3: Xie X, Li Y, Gao D, Zhang Y, Ren Y. Quantitative determination of euphol in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. Biomed Chromatogr. 2014 Sep;28(9):1229-34. doi: 10.1002/bmc.3151. doi: 10.3892/mmr.2013.1650. Epub 2013 Aug 22. doi: 10.4103/0974-8490.147136.
    6: Singh GB, Singh S, Sharma ML, Suri OP, Chopra CL, Ammon HP. Hypotensive activity of 8,24-euphadien-3 beta-ol (euphol). Planta Med. 1989 Dec;55(6):498-500. doi: 10.1016/j.jep.2016.02.025. Epub 2016 Feb 22. doi: 10.1055/s-0034-1368300. Epub 2014 Mar 31. doi: 10.1016/j.jep.2013.08.033. Epub 2013 Sep 2. Chinese. doi: 10.1016/j.chembiol.2009.09.012.

    合成参考文献


    摘要:Planta Medica., 55(498), 1989 []
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知